{"groups":[{"description":"Arm A will receive the CD3/CD28 activated autologous lymphocytes intravenously and subcutaneous injections of \"KLH only\" vaccine.\n\nCD3/CD28: CD3/CD28 activated autologous lymphocytes intravenously","id":"FG000","title":"Arm A"},{"description":"Arm B will receive the CD3/CD28 activated autologous lymphocytes intravenously and subcutaneous injections of ID-KLH Vaccine Myeloma Immunoglobulin Idiotype Vaccine (id-KLH vaccine)\n\nCD3/CD28: CD3/CD28 activated autologous lymphocytes intravenously","id":"FG001","title":"Arm B"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"22"},{"groupId":"FG001","numSubjects":"18"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"17"},{"groupId":"FG001","numSubjects":"15"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"3"}],"type":"NOT COMPLETED"}],"title":"Overall Study Evaluations"},{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"17"},{"groupId":"FG001","numSubjects":"15"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"8"}],"comment":"Only those subjects that had sufficient PBMC samples from pre-vaccination (D0), and Day 30, Day 90 and Day 180 time points for NanoString gene expression analysis were included in the immune response analysis.","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"9"},{"groupId":"FG001","numSubjects":"7"}],"type":"NOT COMPLETED"}],"title":"Immune Response Analysis"}]}